The adenovirus type 5 (Ad5) E4orf6 protein promotes focus formation of primary baby rat kidney (BRK) cells in cooperation with Ad5 E1 proteins. This activity is most likely related to the ability of the E4orf6 protein to bind to p53 and modulate its tumor suppressor functions. In this study we report that transformed BRK cells that stably express E4orf6 in addition to E1A and E1B (ABS cells) displayed multiple additional properties commonly associated with a high grade of oncogenic transformation compared to cells expressing only E1A and E1B (AB cells). These properties included morphological alterations, markedly enhanced growth rates and growth to much higher saturation densities. Following injection into nude mice ABS-derived tumors exhibited accelerated growth and, based on histopathological criteria, proofed to be much more malignant compared to tumors generated by AB cells. Interestingly, these highly transformed properties of ABS cells correlated with a dramatic reduction of p53 steady-state levels which inversely correlated with E4orf6 expression. From these results we conclude that expression of the Ad5 E4orf6 protein (i) confers additional transformed in vitro properties to primary rat cells expressing the Ad5 E1 proteins, and (ii) increases the tumorigenic and malignant potential of these cells in vivo. Our data suggest that the Ad5 E4orf6 protein enhances the intrinsic ability of E1-transformed rat cells to grow in a neoplastic state by completely inactivating p53 tumor suppressor function in combination with the E1A and E1B proteins.
Introduction
Oncogenic transformation of primary rodent cells by human adenoviruses is a multistep process that is mediated by the coordinated expression of viral gene products encoded within early region 1 (E1). E1 contains two transcription units, E1A and E1B, which are both necessary and sucient to stably transform primary cells in culture (see review, Nevins and Vogt, 1996) . The E1A gene products are responsible for the ®rst step in complete transformation. E1A proteins induce cellular DNA synthesis and cell proliferation by virtue of their ability to interact with and modulate the function of several growth-regulatory proteins that control transcription and cell cycle progression, whereupon primary cells with a limited life span can become immortal (see reviews, Moran, 1994; Shenk, 1996 and references therein). E1A-immortalized cells are not completely transformed in that they grow slowly, and not to high densities, are anchorage dependent, and are not tumorigenic. Full manifestation of the transformed phenotype requires expression of two E1B gene products, E1B-19 kDa and E1B-55 kDa, that are individually capable of cooperating with E1A to transform cells via independent but additive pathways (Barker and Berk, 1987; White and Cipriani, 1990; McLorie et al., 1991) . Upon complete transformation, cells expressing E1A and E1B proteins grow rapidly and to high densities, display anchorage-independent growth, and are often tumorigenic (see review, Graham, 1984) .
In recent years it has become apparent that both E1B proteins promote complete cell transformation at least in part by antagonizing programmed cell death (apoptosis) and growth arrest, which result from the induction and metabolic stabilization of the cellular tumor suppressor protein p53 by E1A (Debbas and White, 1993; Lowe and Ruley, 1993) . The E1B-19 kDa protein seems to play a central role in suppression of programmed cell death and inhibits both p53-dependent and p53-independent apoptosis pathways by a mechanism that resembles that of the bcl-2 protooncogene (see review, White, 1996) . The E1B-55 kDa protein, as opposed to the 19-kDa product, directly binds to p53 (Sarnow et al., 1982a) and blocks p53-mediated transcriptional activation (Yew et al., 1994) , required for the induction of growth arrest (El-Deiry et al., 1993; Xiong et al., 1993; Harper et al., 1993) and apoptosis in BRK cells stably expressing E1A (Sabbatini et al., 1995) .
Recently, we and others have shown that adenovirus type 5 (Ad5) contains an additional gene product with transforming activities, which resemble those of the E1B oncoproteins (Moore et al., 1996; Nevels et al., 1997) . The 34-kDa product encoded by open reading frame 6 (orf6) of the E4 transcription unit (E4) can cooperate with E1A in the transformation of primary cells (Moore et al., 1996; Nevels et al., 1997) . E4orf6 also cooperates with E1A and E1B proteins to increase the number of cell transformants. The mechanism by which the E4orf6 protein enhances focus formation is not clear yet but is very likely related to the ability of E4orf6 to interact with and modulate functional properties of p53 (Dobner et al., 1996; Nevels et al., 1997) . The E4orf6 protein can block p53-dependent apoptosis in transient transfection assays (Moore et al., 1996) and can inhibit p53-mediated suppression of E1A plus E1B-19 kDa-induced focus formation of primary rat cells . In addition, expression of E4orf6 in transformed BRK and human 293 cells antagonizes the accumulation of p53 induced by E1A (Moore et al., 1996; Nevels et al., 1997) , an eect that is consistent with the recent observations that p53 steady-state levels are reduced by the E1B-55 kDa and E4orf6 proteins in adenovirus-infected cells (Grand et al., 1994; Querido et al., 1997a) . The molecular basis of this process remains uncertain. Because E4orf6 interacts with both E1B-55 kDa (Sarnow et al., 1984) and p53 (Dobner et al., 1996; Moore et al., 1996; Nevels et al., 1997; Querido et al., 1997a) , it is possible that multiple protein interactions between all three proteins exist in adenovirus-infected and transformed cells that modulate p53 functions and stability.
In this report we describe several biological properties of transformed BRK cell lines expressing the E4orf6 protein. We show that E4orf6-expressing rat cells display additional properties that are commonly found associated with completely, oncogenically transformed cells. Following injection into nude mice ABS cells induced rapidly growing tumors that, based on histopathological criteria, proofed to be much more malignant compared to tumors generated by AB cells. Our data suggest that E4orf6 dramatically enhances the oncogenicity of Ad5 E1-transformed rat cells by antagonizing the stabilization of the tumor suppressor protein p53 in combination with the large E1B protein.
It appears, that these eects are due to mechanisms that involve multiple physical and functional interactions between the adenoviral E1A, E1B and E4orf6 oncoproteins and p53.
Results

Generation and protein analysis of transformed BRK cells
We and others have previously reported that the Ad5 E4orf6 protein can cooperate with Ad5 E1A and E1A plus E1B proteins to transform primary rat epithelial cells in vitro (Moore et al., 1996; Nevels et al., 1997) . In addition, the work by Shenk and coworkers demonstrated that transformed BRK cells containing the E4orf6 protein induced tumors in nude mice more rapidly, and that the adenovirus protein converts nontumorigenic human 293 cells into tumorigenic cells (Moore et al., 1996) . These observations indicated that expression of E4orf6 confers additional growth properties to Ad5 E1-transformed cells that apparently potentiate tumorigenicity. To analyse the biological consequences of E4orf6 expression on the transformed cell phenotype in more detail both Ad5 E1A/E1B-and E1A/E1B/E4orf6-expressing BRK cells were generated, and compared with respect to transformed properties. This was accomplished by transfecting primary BRK cells with plasmids encoding Ad5 E1A and E1B (pXC15) and E1A, E1B plus E4orf6 (pXC15 and pCMV-E4orf6). As expected, cotransfection of pCMV-E4orf6 with pXC15 resulted in a twofold increase of morphologically transformed foci compared with pXC15 alone (Figure 1 ). Many of these foci developed much more rapidly and diered signi®cantly in their morphology from the E1A plus E1B ones. At 21 days after transfection E1A/E1B/E4orf6-induced foci reached on average a size of 7.7 mm while foci lacking the E4orf6 protein averaged 3.5 mm in diameter. Furthermore, the large foci generated in the presence of pCMV-E4orf6 appeared highly multilayered and contained more cells than foci without E4orf6.
Following selection with G418 several dierent pools of foci from cultures transfected with pXC15 (AB cells) and pXC15 plus pCMV-E4orf6 (ABS cells) were generated. Indirect immuno¯uorescence studies revealed that virtually all ABS cells stably expressed the E4orf6 protein in addition to the E1A and E1B gene products (data not shown). Two independent pools of AB cells (AB7 and AB16) and two pools of ABS cells (ABS1 and ABS6) with apparently dierent levels of E4orf6 expression were then selected for further analysis by immunoprecipitation and/or immunoblotting ( Figure 2a ). The levels of E1A and E1B proteins varied among the cell lines. In particular, ABS cells contained lower levels of E1A proteins than AB cells. Also, the p53 steady-state levels were considerably decreased in ABS1 and ABS6 cells (Figure 2a , lanes 3 and 4) relative to AB7 and AB16 cells where the p53 protein accumulated to high levels in the absence of the E4orf6 gene product (Figure 2a , lanes 1 and 2). This observation is consistent with previous ®ndings showing that E4orf6 interferes with the E1A-induced metabolic stabilization of p53 in transformed BRK cells by reducing the half life of the tumor suppressor protein (Moore et al., 1996; Nevels et al., 1997) . Interestingly, in ABS1 cells containing high levels of E4orf6 the p53 steady-state levels were much more reduced than in ABS6 cells which expressed low levels of the adenovirus protein. Thus, the reduction in p53 steady-state levels inversely correlated with the level of E4orf6 expression. Moreover, indirect immuno¯uorescence analyses revealed that the residual low levels of p53 in ABS1 cells were sequestered in cytoplasmic bodies (Zantema et al., 1985; Blair-Zajdel and Blair, 1988 ) which appeared to be much smaller relative to AB7 cells ( Figure 2b ). As opposed to p53 the E4orf6 protein was localized in the nucleus of ABS1 cells (Figure 2c ).
The Ad5 E4orf6 protein induces morphological alterations and enhanced growth rates in transformants expressing adenovirus E1A and E1B proteins
Adenovirus-transformed BRK cells can exhibit a variety of morphological changes depending on the Figure 2 Protein analysis of selected AB and ABS cells. (a) Total cell extracts were prepared in lysis buer. To analyse E1A and E1B-55 kDa expression levels a portion of whole cell extract was separated on a SDS/10% polyacrylamide gel and subjected to immunoblot analysis using anti-E1B-55 kDa monoclonal antibody 2A6 or anti-E1A monoclonal antibody M73 as described. E4orf6 and p53 steady-state levels were analysed by combined immunoprecipitation/immunoblotting. Total cell extracts were subjected to immunoprecipitation using anti-p53 monoclonal antibody PAb421 or anti-E4orf6 monoclonal antibody RSA3. The precipitates were resolved on a 10% protein gel and transferred to nitrocellulose membranes. Then, the p53 and E4orf6 proteins were visualized with anti-p53 polyclonal antibody CM-1 and RSA3, respectively followed by enhanced chemiluminescence. expression of the E1A and E1B oncogenes (Graham, 1984) . While E1A-immortalized BRK cells often resemble the primary parental cells (Houweling et al., 1980; Shiroki et al., 1981; Bernards et al., 1986 ) the apparent morphological changes associated with complete transformation by E1A and E1B are induced by a combinatorial eect of both E1B proteins (White and Cipriani, 1990) . To test whether E4orf6 expression confers additional morphological changes to transformed rat cells expressing E1A and E1B, we compared the morphology of AB and ABS cells (Figure 3 ). ABS1 and ABS6 cells diered signi®cantly from both AB cell lines in that they were smaller with a very round, spherical shape. Additionally, these cells were more refractile and tended to form colonies with sharp edges that resembled the previously described morphology of transformed BRK cells expressing the E1A and E1B-19 kDa proteins (White and Cipriani, 1990) . These E4orf6-dependent changes in morphology suggest that the adenovirus protein, like E1B-19 kDa (White and Cipriani, 1990) , may directly aect the organization of intermediate ®laments in transformed rat cells. Alternatively, since E4orf6 can bind to E1B-55 kDa, the adenovirus protein may indirectly in¯uence the morphology of ABS cells by neutralizing the contribution of E1B-55 kDa (White and Cipriani, 1990) . A number of in vitro growth properties have been described in the past that are associated with malignant transformation of cells. Among these are the ability to grow to high saturation densities and decreased dependence on serum growth factors (Tooze, 1981) . To examine whether E4orf6 expression aects the monolayer growth properties of ABS cells, the growth of these cells was compared to E1A/E1B-expressing AB cells under dierent serum conditions (Figure 4) . In 10% FCS, ABS1 and ABS6 cells showed signi®cantly higher growth rates and achieved up to 60% higher saturation densities than did the control AB7 and AB16 cells. Soon after they reached con¯uency both ABS lines, and in particular ABS1 cells, rapidly acidi®ed the media and detached from the tissue culture plates as a result of cell death. An even greater dierence in growth rates was observed when the cells were grown in 0.1% FCS (Figure 4) . Thus, E4orf6 expression in transformed rat epithelial cells induces decreased density regulation of growth and signi®cantly reduces the dependence on serum growth factors. Because p53 is thought to regulate cell proliferation (Ullrich et al., 1992 ) the dierence in monolayer growth properties between AB and ABS cells might re¯ect the reduced steady-state levels of p53 induced by E4orf6. This assumption was further supported by the fact that ABS1 cells expressing the lowest levels of p53 divided at signi®cant higher rates in 10% and 0.1% FCS than ABS6 cells containing higher amounts of p53. These ®ndings, together with those presented above, demonstrated that the E4orf6 protein is capable of producing morphological alterations associated with the transformed cell phenotype, allowing the cells to grow rapidly and to high densities even under severely reduced serum conditions.
E4orf6 dramatically enhances the growth rates and malignancy of tumors derived from transformed BRK cells
Because the E4orf6-expressing cell lines appeared to be highly transformed in vitro, these cells were tested together with both AB lines for tumorigenicity in nude mice (Table 1) . During a 41-or 42-day observation period all of the animals receiving 1610 6 ABS1 and ABS6 cells developed visually apparent, rapidly growing tumors as early as 14 days after injection while one out of 11 and ®ve out of six animals given the same number of AB7 and AB16 cells, respectively developed small tumors during the same period. Interestingly, tumors induced by ABS1 cells grew 
sizes of over 370 mm 2 already at 28 days after injection ( Figure 5 ). Signi®cantly smaller tumors were obtained with ABS6 cells after the same incubation period. Apparently, the ability of ABS1 and ABS6 cells to induce rapid tumor growth in nude mice inversely correlated with p53 expression levels and was dependent on the expression of the E4orf6 protein.
Both ABS1-and ABS6-induced tumors expressed the E4orf6 protein, verifying their derivation from the E4orf6-expressing cell lines (Figure 6) . Interestingly, all cell lines established from ABS-induced tumors now contained equal levels of the E4orf6 protein, indicating that a change had occurred during neoplastic growth in vivo. A similar result was obtained when E4orf6 expression was analysed in the parental ABS1 and ABS6 cell lines after prolonged passages in tissue culture (data not shown). This suggests that a selection had occurred against transformed cells expressing low levels of the E4orf6 protein. Furthermore, E4orf6-expressing cells derived from tumors exhibited additional morphological alterations, whereas the morphology of tumor cells induced by AB cells did not change signi®cantly in comparison to the parental cell pools. Many of these cells detached from the tissue culture plates and continued to grow in suspension, indicating that these cells completely lost anchorage-dependence.
In support of our results showing that ABS1-and ABS6-induced tumors grew more aggressively than those induced by AB cells, E4orf6-expressing tumors also proved to be more malignant on the basis of histopathological criteria (Figure 7) . AB7 tumor cells growing in nude mice resembled the aspect of a moderately to well dierentiated adenocarcinoma with cell nuclei moderately varying in size and shape. Tumor cell nuclei contain one or two prominent nucleoli. Atypical mitotic ®gures give evidence of malignant cell growth. ABS1-induced tumors show irregularly arranged tumor cells. Atypical mitotic ®gures and multinucleated giant cells appear between polymorphous and polychromatic tumor cells which are signi®cantly smaller than AB7 tumor cells.
Microarchitecture exhibited marked dierences between AB and ABS induced tumors. While AB7 tumors showed moderately to well dierentiated epithelial-like growth characteristics, ABS1-derived tumor cells exhibited features of an extremely undierentiated and highly malignant tumor. Morphometrical analysis revealed an almost threefold celldensity in ABS1 tumors compared with AB7 tumors, and some ABS1 tumors metastasized to axillary lymphnodes draining the tumor region.
Taken together, these in vivo studies clearly demonstrated that E4orf6 expression dramatically enhances the growth and malignancy of tumors derived from transformed BRK cells expressing the Ad5 E1A and E1B proteins.
Discussion
In this report we have demonstrated that the adenovirus E4orf6 protein confers additional growth properties to Ad5 E1-transformed rat cells that dramatically potentiate the oncogenicity of these cells in animals. It is shown for the ®rst time that E4orf6-expressing BRK cells display various phenotypic hallmarks of highly transformed cells, including morphological alterations, enhanced growth rates, reduced density growth regulation and growth in reduced serum. Together with the previous demonstra- tion that E4orf6 cooperates with Ad5 E1 proteins in the transformation of primary rat cells (Moore et al., 1996; Nevels et al., 1997) our results provide further support for the idea that Ad5 E4orf6 is an oncoprotein.
The mechanism by which E4orf6 promotes complete cell transformation is still unknown. The work from Moore et al. (1996) demonstrates that E4orf6 can convert human 293 cells from nontumorigenic to tumorigenic in nude mice. In E4orf6-expressing 293 cells the majority of the p53 protein is localized to the nucleus, whereas in 293 cells lacking the E4orf6 gene product it colocalizes with the E1B-55 kDa protein in cytoplasmic bodies (Moore et al., 1996) . Along with the previous ®ndings that a high level of nuclear p53 correlates with increased oncogenicity of Ad5 E1-transformed 3Y1 rat cells in nude mice (van den Heuvel et al., 1990) , it has been suggested that the E4orf6 protein modi®es the oncogenic properties of adenovirus-transformed cells, at least in part, by altering the localization of p53 (Moore et al., 1996) . As opposed to E4orf6-expressing 293 cells the p53 protein was not located to the nucleus in ABS cells. The residual low levels of p53 in both ABS cells were sequestered in small cytoplasmic bodies adjacent to the nucleus, and no apparent increase of p53 levels in the nucleus was observed by conventional immunofluorescence analyses (Figure 2b) . Identical results were obtained with cells from ABS1-and ABS6-induced tumors, excluding the possibility that a redistribution has occurred during neoplastic growth in vivo. Consequently, a dierence exists in the localization of p53 between E4orf6-expressing transformed human and rat cells. In a recent report it has been demonstrated that E4orf6 directs the nuclear localization of E1B-55 kDa in primate cells, whereas it fails to localize the 55-kDa protein to the nucleus in mouse and rat cells (Goodrum et al., 1996) . This result indicates that the cytoplasmic restriction imposed on p53 might be due to the same mechanism that prevents the E4orf6-dependent nuclear localization of E1B-55 kDa in rodent cells. Thus, at least in Ad5 E1-transformed BRK cells expressing the E4orf6 protein, a redistribution of p53 to the nucleus does not seem to contribute to the transformed cell phenotype.
Previous reports have shown that some p53 mutants are capable of conferring increased tumorigenicity (Dittmer et al., 1993) and can induce a highly transformed phenotype as well as growth advantage in cell lines (Wolf et al., 1984; Chen et al., 1990 ). Since we did not detect abnormal forms of p53, association with hsc70 or recognition by monoclonal antibody PAb240 in ABS cells (data not shown), it is unlikely that a selection for p53 mutations has occurred during transformation by Ad5 E1 and E4orf6 proteins. Instead, our results indicate that E4orf6 increases the oncogenic potential of transformed rat cells through its ability to modulate p53 stability in combination with E1A and E1B proteins. Clearly, the altered growth properties of ABS cells as well as their enhanced oncogenicity in nude mice correlate with a reduction of p53 steady-state levels induced by the E4orf6 protein (Figure 2a) . In fact, the inverse correlation between p53 expression levels and oncogenicity in nude mice (Table  1 and Figure 5 ) strongly indicates that the enhancing eects of E4orf6 may be ultimately linked to its ability to antagonize the metabolic stabilization of p53, which is dependent on the expression of E1A and the large E1B protein (Zantema et al., 1985) . The demonstration that E4orf6 also reduces p53 levels in tumorigenic 293 cells (Moore et al., 1996) provides further support for this view. At present, the molecular basis for this process is still unclear. Studies of adenovirus-infected human and mouse cells have shown that both E1B-55 kDa and E4orf6 are necessary to block the accumulation of p53 (Grand et al., 1994; Querido et al., 1997a) and that this activity is not due to host cell shuto regulated by these proteins but seems to require the binding of p53 to E1B-55 kDa (Querido et al., 1997a) . However, it should be noted, that in E1A/ E4orf6-transformed rat cells the E4orf6 protein alone seems to be sucient to induce a reduction in p53 steady-state levels (Moore et al., 1996) . Although we do not know the basis for this discrepancy, it is possible that these observations are due to the dierent localization of p53 in transformed 293 and ABS cells and/or re¯ect the recently reported dierences concerning the E1A-induced accumulation of p53 between human and rodent cells (Querido et al., 1997b; Chiou and White, 1997) . Nonetheless, the E4orf6-induced reduction of p53 levels in transformed human and rat cells seems to contribute to the tumorigenicity in both cell types. We also noticed that ABS cells contain lower levels of E1A proteins than AB cells (Figure 2a) . The molecular basis for this eect is yet unknown but might be linked to the expression of the E4orf6 protein. Because E1A proteins induce a metabolic stabilization of p53 (Debbas and White, 1993; Lowe and Ruley, 1993) it is conceivable that the reduction of E1A proteins additionally contributes to the decrease of p53 steady-state levels, and, thus to the enhanced oncogenicity of ABS cells.
Considerable evidence suggests that p53-dependent apoptosis and growth arrest are important parts of the tumor suppressor phenotype that aects transformation of activated cellular or viral oncogenes (Lowe and Ruley, 1993; Debbas and White, 1993) , as well as tumor growth and progression (Symonds et al., 1994; Hundley et al., 1997) . It has been well established that the ability of E1B-19 kDa and E1B-55 kDa to inhibit p53-dependent apoptosis and growth suppression is an integral part by which both proteins promote complete transformation of primary cells in cooperation with E1A (White, 1994) . However, the dierence in the in vitro growth properties between AB and ABS cells as well as the weak oncogenicity of Ad5 E1A/E1B-expressing rat cells indicates that the two E1B proteins do not completely inhibit the processes mediated by p53. Although the majority of p53 and E1B-55 kDa proteins is immunologically restricted to cytoplasmic bodies in AB cells (Figure 2b ) previous studies have shown that cytoplasmic sequestration of p53 is not the principal mechanism by which E1B-55 kDa inhibits p53. The work from Berk and coworkers indicates that E1B-55 kDa functions as a transcriptional repressor that is targeted to p53-responsive genes by binding to p53 (Yew and Berk, 1992; Yew et al., 1994) . Moreover, these studies indicate that sucient p53 can enter the nucleus of transformed cells to permit activation of reporter genes even after cytoplasmic sequestration of p53 by the large E1B protein (Yew et al., 1994) . Thus, it might be possible that a minor portion of the high levels of p53 present in AB cells may not be completely inhibited by E1B-55 kDa in the nucleus and thus may partially impede cell proliferation. Consequently, a substantial reduction of p53 levels induced by E4orf6 would result in reduced growth inhibition and/or apoptosis leading to enhanced cell proliferation and rapid tumor growth, just as we have observed for both ABS cell lines (Figures 4 and 5) . Given the fact that both E1B proteins can block the apoptotic response induced by E1A it seems unlikely that the ability of E4orf6 to inhibit p53-dependent apoptosis (Moore et al., 1996) is a major factor that further contributes to enhanced cell proliferation. Indeed, the dramatically enhanced growth properties of ABS cells in vitro and in vivo (Figures 4 and 5) suggest that the E4orf6-dependent reduction of p53 steady-state levels primarily induces enhanced cell proliferation rather than reduced apoptosis.
The role of p53-mediated transcription in the induction of growth arrest has been well documented (El-Deiry et al., 1993; Xiong et al., 1993; Harper et al., 1993) . In addition, it has been demonstrated that p53-dependent growth suppression requires both the amino-and carboxy-terminal regions of p53 (Pietenpol et al., 1994) . Because, both E1B-55 kDa and E4orf6 inhibit p53-activated transcription (Yew and Berk, 1992; Dobner et al., 1996) , it is possible that they cooperate to block growth arrest induced by the residual low levels of p53. Furthermore, because E1B-55 kDa and E4orf6 bind to dierent domains on p53 (Lin et al., 1994; Dobner et al., 1996) , it is also possible that both proteins bind to p53 simultaneously to antagonize this activity; although at present there is no direct evidence that such a trimeric complex exists. In summary, our results indicate that E4orf6 enhances the intrinsic ability of E1-transformed rat cells to grow in a neoplastic state by dierent but synergistical mechanisms that completely inactivate p53 tumor suppressor functions. This hypothesis is consistent with the ®ndings that loss of p53 signi®cantly alters the growth characteristics of cells in vitro (Harvey et al., 1993) and enhances malignant progression and aggressive tumor growth in vivo (Kemp et al., 1993; Symonds et al., 1994) .
Based upon the fact that E4orf6 expression contributes signi®cantly to transformation and tumor progression by antagonizing p53 tumor suppressor activities we recommend that the E4orf6 gene should be removed from all adenovirus vectors presently being considered for gene therapy applications (Bischo et al., 1996; Heise et al., 1997) .
Materials and methods
Plasmids and cell lines
The following plasmids were used in this study: pXC15 (pAd5 XhoI-C) contains the left end (1 ± 15.5 map units) of the Ad5 genome, and expresses the E1A and E1B proteins (Logan et al., 1984) . Plasmids pCMV-E4orf6 and pCMV-E1A produce the Ad5 wild-type E4orf6 and E1A proteins from the cytomegalovirus (CMV) immediate early promoter, respectively Neill et al., 1990) .
Sprague-Dawley rats were randomly bred in the university's animal facilities under standardized conditions (Spruû et al., 1996) . Primary cultures of BRK cells were prepared from kidneys of 6-day-old rats as described , and grown in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS). For transformation assays subcon¯uent cells were transfected 2 days postplating by the calcium phosphate procedure (Graham and van der Eb, 1973) with salmon sperm carrier and plasmid DNAs exactly as described . Three weeks after transfection foci were either stained with crystal violet (1% in 25% methanol) or pooled and expanded into cell lines. The medium was DMEM containing 10% FCS and 400 mg/ml G418 (Geneticin; GIBCO) for AB16, ABS1 and ABS6 cells or the same medium without Geneticin for AB7 cells. For growth studies 3610 4 cells were initially plated onto 6-well dishes in culture medium supplemented with 10 or 0.1% FCS. The medium was replaced every 48 h and viable cells from duplicated dishes were counted using an improved Neubauer counting chamber. Cell viability was determined by Trypan blue dye exclusion.
To analyse protein expression in tumor tissues, the tumors were removed and incubated with 1 mg/ml dispase-collagenase (Boehringer ± Mannheim) at 378C for 3 ± 4 h. The single cell suspension was then seeded on tissue culture dishes and expanded in DMEM containing 10% FCS and 400 mg/ml G418.
Protein analyses
For the analysis of proteins total cell extracts were prepared in lysis buer (50 mM Tris-chloride [pH 8.0], 150 mM NaCl, 0.1% sodium dodecyl sulfate [SDS], 1% Nonidet P-40, 0.5% sodium deoxycholate, 1 mM phenylmethylsulfonyl¯uoride [PMSF], 0.3 mM aprotinin, 1 mM leupeptin, 1 mM pepstatin) and subjected to immunoprecipitation or immunoblotting using anti-E1B-55 kDa (2A6, ref. Sarnow et al., 1982b) , anti-E1A (M73, ref. Harlow et al., 1985) , anti-E4orf6 (RSA3, ref. Marton et al., 1990) and anti-p53 (PAb421, ref. Harlow et al., 1981 ; CM-1, kindly provided by D Lane) monoclonal antibodies as described earlier . The immune complexes were resuspended in SDS-sample buer, separated on 10 or 12% SDS-polyacrylamide gels and blotted onto nitrocellulose membranes by using an electroblotting transfer system. The proteins were visualized with the appropriate antibody followed by a secondary antibody linked to horseradish peroxidase (Amersham) and enhanced chemiluminescence (ECL, Amersham).
For indirect immuno¯uorescence studies cells were grown on glass cover slips. They were ®xed with methanol for 20 min at 7208C and incubated in phosphate-buered saline (PBS) containing 5% non-fat dry milk for 1 h at room temperature. After that, samples were reacted with a hybridoma supernatant containing monoclonal antibody PAb421 for 1 h at room temperature, washed three times with PBS and incubated with 10 mg of¯uorescein-conjugated rabbit antibodies speci®c for mouse immunoglobulins (Dako) for 1 h. After being washed ®ve times in PBS, the samples were mounted in mounting medium (Vector Lab.). Samples were examined and photographed with an Olympus AX 70 microscope by using epi¯uorescence illumination.
Establishment and analysis of solid tumors in nude mice
Cells were harvested with trypsin, washed twice in PBS and resuspended in serum-free DMEM at a concentration of 1610 7 cells/ml. NMRI (nu/nu) mice with a mean body weight of 20 g were injected subcutaneously with 1610 6 cells. Tumor growth kinetics was recorded by weekly measurement of tumor diameters at the inoculation site (region of the thoriac mammary fat pad) with an electronic caliper. Tumor areas were calculated as the product of two perpendicular diameters, one measured across the greatest width of the tumor. For ethical reasons the mice were killed after the tumors reached a maximum size of approximately 300 mm 2 or 6 weeks after injection. For histological analysis tumors as well as surrounding connective tissue and adhering skin regions were ®xed in Bouin's solution and prepared for routine paran histology. Sections (5 mm) were stained with HE or according to the Masson and Golder method modi®ed by Jerusalem (MGJ).
